foxo4-dri cancer The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound Development of a novel senolytic
Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine FOXO4 DRI 10mg FOX04 DRI Apollo Peptide Sciences FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data FOXO4 DRI Peptide Nationwide Peptides By National Science Labs, LLC Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv
Pay in 4 interest-free payments of $6.23 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6





